Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and Medivir have entered into an exclusive agreement for the commercialisation of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets.
Subscribe to our email newsletter
GSK and Medivir claimed that Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.
As per the terms of the agreement, GSK gets exclusive rights for commercialisation of the OTC drug Xerclear as part of the Zovirax franchise, across multiple markets, including Europe, Russia, Japan, India, Australia and New Zealand.
GSK is expected to take responsibility for funding ongoing and future commercial development of Xerclear in all territories covered by the agreement.
In addition to funding the commercial development of Xerclear, GSK is expected to pay up to EUR3m in up-front and pre-launch milestones and up to double-digit royalties on sales to Medivir for the exclusive rights.
Ron Long, CEO of Medivir, said: “We are pleased to have partnered Xerclear with GlaxoSmithKline Consumer Healthcare. This represents a major step in the global commercialisation of our cold sore product.”